OnKure CFO auto-sells 303 shares for tax withholding

OnKure Therapeutics, Inc.’s Chief Financial Officer Jason A. Leverone reported an automatic sale of 303 shares of Class A Common Stock at a weighted average price of $4.3963 per share.

Rhea-AI Filing Summary

OnKure Therapeutics, Inc.’s Chief Financial Officer Jason A. Leverone reported an automatic sale of 303 shares of Class A Common Stock at a weighted average price of $4.3963 per share. The shares were sold to cover tax withholding obligations tied to vesting RSUs. After this transaction, he directly holds 18,802 shares, including 3,105 shares acquired through the 2024 Employee Stock Purchase Plan on May 20, 2026.

Insider Trade Summary

Net Seller: 303 shares

Net Sell 1 txn

Insider Leverone Jason A.

Role Chief Financial Officer

Sold 303 shs ($1K)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock	303	$4.3963	$1K

Holdings After Transaction: Class A Common Stock — 18,802 shares (Direct)

Footnotes (4)

1. F1. These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan.
2. F2. This transaction was executed in multiple trades at prices ranging from $4.27 to $4.54. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
3. F3. Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
4. F4. Includes 3,105 shares acquired under the Issuer's 2024 Employee Stock Purchase Plan on May 20, 2026.

Key Figures

Shares sold: 303 shares Weighted average sale price: $4.3963 per share Shares held after transaction: 18,802 shares +1 more

4 metrics

Shares sold 303 shares Automatic sale to cover tax withholding

Weighted average sale price $4.3963 per share Multiple trades between $4.27 and $4.54

Shares held after transaction 18,802 shares Direct Class A Common Stock ownership after sale

ESPP shares included 3,105 shares Acquired under 2024 Employee Stock Purchase Plan on May 20, 2026

Key Terms

restricted stock units ("RSUs"), 2023 RSU Equity Incentive Plan, weighted average sale price, 2024 Employee Stock Purchase Plan

4 terms

restricted stock units ("RSUs") financial

"These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs")"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

2023 RSU Equity Incentive Plan financial

"pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan"

weighted average sale price financial

"The price reported above reflects the weighted average sale price"

2024 Employee Stock Purchase Plan financial

"Includes 3,105 shares acquired under the Issuer's 2024 Employee Stock Purchase Plan on May 20, 2026"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did OnKure Therapeutics (OKUR) disclose for its CFO?

OnKure Therapeutics’ CFO, Jason A. Leverone, reported an automatic sale of 303 Class A Common shares. The shares were sold solely to cover tax withholding obligations related to vesting restricted stock units, rather than a discretionary open-market sale.

At what price were the OnKure Therapeutics (OKUR) shares sold in this Form 4?

The reported transaction used a weighted average sale price of $4.3963 per share, based on multiple trades executed between $4.27 and $4.54. This average reflects the aggregate pricing of all individual trades executed that day.

Why did the OnKure Therapeutics (OKUR) CFO sell 303 shares?

The 303 shares were automatically sold to satisfy tax withholding obligations arising from vesting restricted stock units under OnKure’s 2023 RSU Equity Incentive Plan. This type of transaction is a routine tax-related disposition rather than a voluntary share sale.

How many OnKure Therapeutics (OKUR) shares does the CFO hold after this transaction?

After the tax-related sale, CFO Jason A. Leverone directly holds 18,802 shares of Class A Common Stock. This total includes 3,105 shares acquired through the company’s 2024 Employee Stock Purchase Plan on May 20, 2026, as noted in the filing.

What are RSUs in the context of OnKure Therapeutics (OKUR) insider filing?

Restricted stock units (RSUs) are awards that convert into shares of Class A Common Stock upon vesting, subject to conditions. Each RSU represents a contingent right to receive one share, and vesting can trigger tax obligations that may be settled through automatic share sales.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/24/2026 - 07:27 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Leverone Jason A.

(Last) (First) (Middle)

C/O ONKURE THEREAPEUTICS, INC.

6707 WINCHESTER CIRCLE, SUITE 400

(Street)

BOULDER COLORADO 80301

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
OnKure Therapeutics, Inc. [ OKUR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	06/22/2026		S(1)		303	D	$4.3963(2)	18,802(3)(4)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan.

2. This transaction was executed in multiple trades at prices ranging from $4.27 to $4.54. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

3. Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU.

4. Includes 3,105 shares acquired under the Issuer's 2024 Employee Stock Purchase Plan on May 20, 2026.

	/s/ Rogan Nunn, by power of attorney	06/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)